drugset / Trial / NCT05832684

Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

NCT05832684 ↗

Phase 1/2 Active not recruiting 24 enrolled Chigenovo Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the safety and efficacy of ZVS101e administered by subretinal injection in subjects with Bietti's crystalline dystrophy (BCD) and to select the optimal effective dose.

Timeline

Start
2023-02-20
Primary completion
2024-07-23
Completion
2028-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ZVS101e Gene therapy (AAV / viral vector) — Other